These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
351 related articles for article (PubMed ID: 12171902)
1. 5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Coral S; Sigalotti L; Altomonte M; Engelsberg A; Colizzi F; Cattarossi I; Maraskovsky E; Jager E; Seliger B; Maio M Clin Cancer Res; 2002 Aug; 8(8):2690-5. PubMed ID: 12171902 [TBL] [Abstract][Full Text] [Related]
2. Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications. Coral S; Sigalotti L; Colizzi F; Spessotto A; Nardi G; Cortini E; Pezzani L; Fratta E; Fonsatti E; Di Giacomo AM; Nicotra MR; Natali PG; Altomonte M; Maio M J Cell Physiol; 2006 Apr; 207(1):58-66. PubMed ID: 16252259 [TBL] [Abstract][Full Text] [Related]
3. The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. Almstedt M; Blagitko-Dorfs N; Duque-Afonso J; Karbach J; Pfeifer D; Jäger E; Lübbert M Leuk Res; 2010 Jul; 34(7):899-905. PubMed ID: 20381863 [TBL] [Abstract][Full Text] [Related]
4. Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications. Fonsatti E; Nicolay HJ; Sigalotti L; Calabrò L; Pezzani L; Colizzi F; Altomonte M; Guidoboni M; Marincola FM; Maio M Clin Cancer Res; 2007 Jun; 13(11):3333-8. PubMed ID: 17545540 [TBL] [Abstract][Full Text] [Related]
5. The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma. Natsume A; Wakabayashi T; Tsujimura K; Shimato S; Ito M; Kuzushima K; Kondo Y; Sekido Y; Kawatsura H; Narita Y; Yoshida J Int J Cancer; 2008 Jun; 122(11):2542-53. PubMed ID: 18240144 [TBL] [Abstract][Full Text] [Related]
6. Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine. Sigalotti L; Fratta E; Coral S; Tanzarella S; Danielli R; Colizzi F; Fonsatti E; Traversari C; Altomonte M; Maio M Cancer Res; 2004 Dec; 64(24):9167-71. PubMed ID: 15604288 [TBL] [Abstract][Full Text] [Related]
7. Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: immunotherapeutic implications. Calabrò L; Fonsatti E; Altomonte M; Pezzani L; Colizzi F; Nanni P; Gattei V; Sigalotti L; Maio M J Cell Physiol; 2005 Feb; 202(2):474-7. PubMed ID: 15389591 [TBL] [Abstract][Full Text] [Related]
8. The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma. Ayyoub M; Taub RN; Keohan ML; Hesdorffer M; Metthez G; Memeo L; Mansukhani M; Hibshoosh H; Hesdorffer CS; Valmori D Cancer Immun; 2004 Aug; 4():7. PubMed ID: 15298487 [TBL] [Abstract][Full Text] [Related]
9. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation. Reu FJ; Bae SI; Cherkassky L; Leaman DW; Lindner D; Beaulieu N; MacLeod AR; Borden EC J Clin Oncol; 2006 Aug; 24(23):3771-9. PubMed ID: 16801630 [TBL] [Abstract][Full Text] [Related]
10. Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor. Dubovsky JA; McNeel DG Prostate; 2007 Dec; 67(16):1781-90. PubMed ID: 17929270 [TBL] [Abstract][Full Text] [Related]
11. Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine. Karpf AR; Lasek AW; Ririe TO; Hanks AN; Grossman D; Jones DA Mol Pharmacol; 2004 Jan; 65(1):18-27. PubMed ID: 14722233 [TBL] [Abstract][Full Text] [Related]
12. Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2'-deoxycytidine (5-AZA-CdR). Coral S; Sigalotti L; Gasparollo A; Cattarossi I; Visintin A; Cattelan A; Altomonte M; Maio M J Immunother; 1999 Jan; 22(1):16-24. PubMed ID: 9924695 [TBL] [Abstract][Full Text] [Related]
13. Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications. Sigalotti L; Coral S; Altomonte M; Natali L; Gaudino G; Cacciotti P; Libener R; Colizzi F; Vianale G; Martini F; Tognon M; Jungbluth A; Cebon J; Maraskovsky E; Mutti L; Maio M Br J Cancer; 2002 Mar; 86(6):979-82. PubMed ID: 11953832 [TBL] [Abstract][Full Text] [Related]
14. NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine. Pollack SM; Li Y; Blaisdell MJ; Farrar EA; Chou J; Hoch BL; Loggers ET; Rodler E; Eary JF; Conrad EU; Jones RL; Yee C PLoS One; 2012; 7(2):e32165. PubMed ID: 22384167 [TBL] [Abstract][Full Text] [Related]
15. Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen. Dubovsky JA; McNeel DG; Powers JJ; Gordon J; Sotomayor EM; Pinilla-Ibarz JA Clin Cancer Res; 2009 May; 15(10):3406-15. PubMed ID: 19401350 [TBL] [Abstract][Full Text] [Related]
16. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Korangy F; Ormandy LA; Bleck JS; Klempnauer J; Wilkens L; Manns MP; Greten TF Clin Cancer Res; 2004 Jul; 10(13):4332-41. PubMed ID: 15240519 [TBL] [Abstract][Full Text] [Related]
17. NY-ESO-1 may be a potential target for lung cancer immunotherapy. Lee L; Wang RF; Wang X; Mixon A; Johnson BE; Rosenberg SA; Schrump DS Cancer J Sci Am; 1999; 5(1):20-5. PubMed ID: 10188057 [TBL] [Abstract][Full Text] [Related]
18. Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia. Atanackovic D; Luetkens T; Kloth B; Fuchs G; Cao Y; Hildebrandt Y; Meyer S; Bartels K; Reinhard H; Lajmi N; Hegewisch-Becker S; Schilling G; Platzbecker U; Kobbe G; Schroeder T; Bokemeyer C; Kröger N Am J Hematol; 2011 Nov; 86(11):918-22. PubMed ID: 21898529 [TBL] [Abstract][Full Text] [Related]
19. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Liu G; Ying H; Zeng G; Wheeler CJ; Black KL; Yu JS Cancer Res; 2004 Jul; 64(14):4980-6. PubMed ID: 15256472 [TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory activity of SGI-110, a 5-aza-2'-deoxycytidine-containing demethylating dinucleotide. Coral S; Parisi G; Nicolay HJ; Colizzi F; Danielli R; Fratta E; Covre A; Taverna P; Sigalotti L; Maio M Cancer Immunol Immunother; 2013 Mar; 62(3):605-14. PubMed ID: 23138873 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]